A polymorphism in 5-alpha-reductase (SRD5A2) gene shows novel association with prostate cancer

被引：0
|
作者：
Minarik, M.
Benesova, L.
Fantova, L.
Heracek, J.
Urban, M.
Loukola, A.
机构：
[1] Genomac Int, Lab Mol Genet & Oncol, Prague, Czech Republic
[2] Charles Univ Prague, Fac Med 3, Prague, Czech Republic
[3] Univ Helsinki, Finnish Genome Ctr, Helsinki, Finland
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2007年 / 6卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(07)60105-5
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [21] Effect of SRD5A2 genotype on pharmacodynamics of 5-alpha-reductase inhibitor analyzed by PK-PD modeling.
    Chung, J
    Cho, J
    Lim, H
    Oh, D
    Yi, S
    Jang, I
    Shin, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P12 - P12
  • [22] SUPPRESSION OF STEROID-5-ALPHA-REDUCTASE 2 (SRD5A2) IN HUMAN PROSTATE IS REGULATED BY EPIGENETIC MODIFICATIONS
    Ge, Rongbin
    Wang, Zongwei
    Wu, Shulin
    Wu, Chin-Lee
    Tabatabaei, Shahin
    Olumi, Aria
    JOURNAL OF UROLOGY, 2016, 195 (04): : E598 - E598
  • [23] Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients
    Margiotti, K
    Sangiuolo, F
    De Luca, A
    Froio, F
    Pearce, CL
    Ricci-Barbini, V
    Micali, F
    Bonafè, M
    Franceschi, C
    Dallapiccola, B
    Novelli, G
    Reichardt, JKV
    DISEASE MARKERS, 2000, 16 (3-4) : 147 - 150
  • [24] The association of 5α-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population
    Onen, Ilke Hacer
    Ekmekci, Abdullah
    Eroglu, Muzaffer
    Polat, Fazli
    Biri, Hasan
    DNA AND CELL BIOLOGY, 2007, 26 (02) : 100 - 107
  • [25] Association between steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and prostate cancer risk: a meta-analysis study
    Zhang, Gang
    Yin, Tao
    Zhang, Bin
    Liang, Ming
    Ding, Jiandong
    Cao, Longqiao
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (04): : 7312 - 7324
  • [26] Regulation of steroid-5-alpha-reductase 2 (SRD5A2) in human prostate by epigenetic modifications.
    Olumi, Aria F.
    Ge, Rongbin
    Wang, Zongwei
    Wu, Shulin
    Tabetabaei, Shahin
    Wu, Chin-Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [27] Association among polymorphisms in the steroid 5α-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population
    Paz-y-Mino, Cesar
    Witte, Tania
    Robles, Paulo
    Llumipanta, William
    Diaz, Myriam
    Arevalo, Melissa
    CANCER GENETICS AND CYTOGENETICS, 2009, 189 (02) : 71 - 76
  • [28] Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population
    Li, ZH
    Habuchi, T
    Mitsumori, K
    Kamoto, T
    Kinoshitu, H
    Segawa, T
    Ogawa, O
    Kato, T
    JOURNAL OF UROLOGY, 2003, 169 (06): : 2378 - 2381
  • [29] Identification and characterization of somatic steroid 5α-reductase (SRD5A2) mutations in human prostate cancer tissue
    Nick Makridakis
    Abebe Akalu
    Juergen K V Reichardt
    Oncogene, 2004, 23 : 7399 - 7405
  • [30] The A49T mutation in the SRD5A2 gene increases risk for aggressive prostate cancer and prostatic steroid 5-alpha reductase activity
    Reichardt, J
    Makridakis, N
    Pike, M
    Crocitto, L
    Kolonel, L
    Ross, R
    Henderson, B
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A209 - A209
12345